Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy

Ke-Hung Tsui, Yu-Hsiang Lin, Cheng-Pang Hou, Horng-Heng Juang, Chien-Lun Chen, Phei-Lang Chang, IH Shao
  • Drug Design Development and Therapy, October 2014, Taylor & Francis
  • DOI: 10.2147/dddt.s72197

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication


The following have contributed to this page: Horng-Heng Juang and professor Ke-Hung Tsui